Dupilumab Mechanism and Clinical Classification

Clinical Guidelines and Safety Profile

• The European Society for Medical Oncology (ESMO) lists dupilumab under "Anti-IL-4Rα therapy" within the broader category of biologic disease-modifying anti-rheumatic drugs (bDMARDs), distinguishing it from conventional immunosuppressants like mycophenolate mofetil, calcineurin inhibitors, cyclophosphamide, methotrexate, and azathioprine 1, 2, 3
• The American Academy of Dermatology guidelines do not require laboratory monitoring before initiation or during dupilumab treatment, in contrast to true immunosuppressants that require baseline and ongoing monitoring of complete blood counts, liver enzymes, renal function, and infection screening 4
• Dupilumab does not require the extensive baseline screening or ongoing laboratory monitoring mandated for immunosuppressants, according to the American Academy of Dermatology 4
• Patients can receive dupilumab without the infection precautions, live vaccine restrictions, or organ toxicity monitoring required for cyclosporine, methotrexate, or azathioprine, as per the American Academy of Dermatology guidelines 4

Dupilumab and Infection Risk

Mechanism of Action

• Dupilumab selectively blocks IL-4 and IL-13 signaling (type 2 inflammation) without broadly suppressing the immune system, unlike traditional immunosuppressants such as cyclosporine, methotrexate, or TNF-alpha inhibitors, as reported by the Journal of Microbiology, Immunology and Infection 5

Diagnostic Considerations

• If osteomyelitis is suspected in a patient on dupilumab, standard diagnostic workup should proceed, including plain radiographs initially, followed by MRI if clinical suspicion persists, as recommended by the American College of Radiology 6 7
• The diagnosis of osteomyelitis requires isolation of bacteria from bone specimens with histological evidence of inflammatory cells and osteonecrosis, regardless of what medications the patient is taking, according to Clinical Infectious Diseases 6